Two stocks in Healthcare
AstraZeneca vs Oxford Biomedica: profit, growth, debt and price compared
AstraZeneca is stronger on 4 of 6 figures: profit margin, debt, price for its expected profit and price trend. Oxford Biomedica is stronger on 1: sales growth.
Save both stocks to your watchlist and revisit their latest fundamentals.
| AstraZenecaAZN.L | Oxford BiomedicaOXB.L | |
|---|---|---|
| Net margin | Stronger: 17.7% | −23.2% |
| Revenue growth, past year | +6.70% | Stronger: +9.00% |
| Debt to equity | Stronger: 66.2% | 273.1% |
| Forward P/E | Stronger: 16.1× | Loss |
| Dividend yield | 1.73% | — |
| Analysts | Buy · 22 | Buy · 8 |
| From its 200-day average | Stronger: +5.0% | −5.2% |
Share price over the past year
- AstraZeneca0.0%
- Oxford Biomedica−13.2%
20 Nov 202518 Nov 2026
AstraZeneca or Oxford Biomedica: which is stronger?
- AZN.L
Which is more profitable?
AstraZeneca keeps more of each sale as profit: 17.7% against −23.2%.
- OXB.L
Which is growing its sales faster?
Oxford Biomedica is growing its sales faster: +9.00% over the past year, against +6.70%.
- AZN.L
Which has borrowed less?
AstraZeneca has borrowed less: its debt is 66.2% of what its shareholders own, against 273.1% for Oxford Biomedica.
- AZN.L
Which costs less for the profit it is expected to make?
AstraZeneca is expected to make a profit over the next year, where Oxford Biomedica is expected to make a loss.
Which pays more in dividends?
AstraZeneca pays 1.73% a year in dividends for what a share costs, where Oxford Biomedica pays none.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- AZN.L
Which is in the stronger price trend?
AstraZeneca's price is in the stronger trend: 5.0% above its 200-day average, against 5.2% below.
What each company does
AZN.LAstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Reports results on 9 February 2027
OXB.LOxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
Reports results on 25 March 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.